Home - Products - Others - Other Targets - α-2,3-sialyltransferase-IN-1

α-2,3-sialyltransferase-IN-1

CAS No. 881179-06-2

α-2,3-sialyltransferase-IN-1( —— )

Catalog No. M33184 CAS No. 881179-06-2

α-2,3-sialyltransferase-IN-1 is a noncompetitive inhibitor of α-2,3-sialyltransferase [IC50: 6 μM].

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 1398 In Stock
50MG 1822 In Stock
100MG 2250 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    α-2,3-sialyltransferase-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    α-2,3-sialyltransferase-IN-1 is a noncompetitive inhibitor of α-2,3-sialyltransferase [IC50: 6 μM].
  • Description
    α-2,3-sialyltransferase-IN-1 (Lith-O-Asp analog) is a noncompetitive α-2,3-sialyltransferase inhibitor with an IC50 of 6 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    881179-06-2
  • Formula Weight
    491.66
  • Molecular Formula
    C28H45NO6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 103.7 mg/mL (210.92 mM)
  • SMILES
    [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)[C@H](N)CC(O)=O)[C@H](C)CCC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chang KH, et al. Lithocholic acid analogues, new and potent alpha-2,3-sialyltransferase inhibitors. Chem Commun (Camb). 2006 Feb 14;(6):629-31.?
molnova catalog
related products
  • Vardenafil hydrochlo...

    Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

  • [Nle10]-Neurokinin A...

    [Nle10]-Neurokinin A (4-10)

  • Nemorubicin

    Nemorubicin is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile.?